LTZ Therapeutics

Based in Redwood City, United States and founded in 2022, LTZ Therapeutics Inc. , trading under the name LTZ Therapeutics, provides innovative immunotherapy drugs for the healthcare sector. The company maintains operational bases in California and Shenzhen, China, and is led by Co-founder and Chief Executive Officer Robert Li. It has established strategic transactions with global pharmaceutical companies such as Eli Lilly and GSK.

In May 2026, the company raised USD 38 million in venture funding led by GL Ventures. The company focuses on the research and development of new immunotherapies, and its main products are based on the Myeloid Engager Platform. The product pipeline includes LTZ-301, LTZ-232, and LTZ-233. LTZ-301 is a new myeloid adapter bispecific antibody that can be used to treat relapsed or refractory non-Hodgkin's lymphoma.

LTZ-232 and LTZ-233 are mainly targeted at solid tumors. The original new drugs developed by the company are used in the fields of tumors and autoimmune diseases. The company generates revenue through the research and development of original new drugs in the oncology and autoimmune fields, alongside strategic collaborations and licensing transactions with multinational pharmaceutical corporations. The company plans to use the latest funding to accelerate the development of its Universal Myeloid Cell Engager (U-MCE) immunotherapy pipeline, support the ongoing Phase 1 clinical study of its lead asset LTZ-301 in the US, and advance the Investigational New Drug (IND) filing and Phase 1 initiation of its second asset, LTZ-232.